<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Theoretic concerns exist that children with <z:mp ids='MP_0002657'>chondrodysplasia</z:mp> will not grow in response to growth hormone (GH) therapy because of an inability of the abnormal growth cartilage to respond </plain></SENT>
<SENT sid="1" pm="."><plain>Experience to date, however, suggests that there is an increase in growth velocity, especially during the first year of treatment, which may be beneficial </plain></SENT>
<SENT sid="2" pm="."><plain>Growth has increased during the early phases of GH therapy in both patients with <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> and patients with hypochondroplasia </plain></SENT>
<SENT sid="3" pm="."><plain>Fourteen patients with <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> in the National Cooperative Growth Study have been treated with an average dose of GH of 0.317 mg/kg per week for an average of 2.6 years and have gained an average of 0.7 SD in height </plain></SENT>
<SENT sid="4" pm="."><plain>Twenty patients with hypochondroplasia in the National Cooperative Growth Study have been treated with an average dose of GH of 0.317 mg/kg per week for an average of 2.6 years and have gained an average of 0.7 SD in height </plain></SENT>
<SENT sid="5" pm="."><plain>These data suggest that the abnormal growth cartilage in patients with <z:mp ids='MP_0002657'>chondrodysplasia</z:mp> responds to GH therapy </plain></SENT>
<SENT sid="6" pm="."><plain>The effect on final height cannot be predicted with the currently available data </plain></SENT>
</text></document>